For Research Use Only

Alpha galactosidase A Polyclonal antibody

Catalog Number: 19877-1-AP

1 Publications



Basic Information	Catalog Number: 19877-1-AP	GenBank Accession Number BC002689	Purification Method: Antigen affinity purification
	Size:	GenelD (NCBI):	Recommended Dilutions:
	150ul , Concentration: 500 µg/ml by	2717	WB 1:500-1:3000
	Nanodrop and 287 µg/ml by Bradford method using BSA as the standard;	UNIPROT ID: P06280	IF/ICC 1:10-1:100
	Source: Rabbit	Full Name: galactosidase, alpha	
	lsotype: IgG	Calculated MW: 49 kDa	
	Immunogen Catalog Number: AG7505	Observed MW: 49 kDa	
Applications	Tested Applications:	Positive Controls:	
	WB, IF/ICC, ELISA	WB:	HEK-293 cells,
	Cited Applications: WB	IF/IC	C : HepG2 cells,
	Species Specificity: human, mouse, rat		
	Cited Species: human		
	GLA also named as Melibiase Agals		A, Belongs to the glycosyl hydrolase 27 family
Background Information	hydrolysis of terminal, non-reducing oligosaccharides, galactomannans ar	nd galactolipids. Fabry diseas of GLA. Enzyme replacement t	n alpha-D-galactosides, including galactose e is an X-linked lysosomal storage disorder herapy (ERT) with GLA is currently the most sosomal storage disease.
	hydrolysis of terminal, non-reducing oligosaccharides, galactomannans ar resulting from the deficient activity o effective therapeutic strategy for pati	nd galactolipids. Fabry diseas of GLA. Enzyme replacement t	e is an X-linked lysosomal storage disorder herapy (ERT) with GLA is currently the most
Background Information	hydrolysis of terminal, non-reducing oligosaccharides, galactomannans ar resulting from the deficient activity o effective therapeutic strategy for pati	nd galactolipids. Fabry diseas of GLA. Enzyme replacement th ients with Fabry disease, a lys med ID Journal	e is an X-linked lysosomal storage disord herapy (ERT) with GLA is currently the mos sosomal storage disease. Application
	hydrolysis of terminal, non-reducing oligosaccharides, galactomannans ar resulting from the deficient activity o effective therapeutic strategy for pati Author Pub	nd galactolipids. Fabry diseas of GLA. Enzyme replacement th ients with Fabry disease, a lys med ID Journal 198959 Int J Biol Sci er shipment.	e is an X-linked lysosomal storage disorder herapy (ERT) with GLA is currently the most sosomal storage disease. Application

For technical support and original validation data for this product please contact:T: 1 (888) 4PTGLAB (1-888-478-4522) (toll freeE: proteintech@ptglab.comin USA), or 1(312) 455-8498 (outside USA)W: ptglab.com

This product is exclusively available under Proteintech Group brand and is not available to purchase from any other manufacturer.

Selected Validation Data





HEK-293 cells were subjected to SDS PAGE followed by western blot with 19877-1-AP (Alpha galactosidase A antibody) at dilution of 1:1500 incubated at room temperature for 1.5 hours. Immunofluorescent analysis of HepG2 cells, using GLA antibody 19877-1-AP at 1:25 dilution and Rhodamine-labeled goat anti-rabbit IgG (red).